Filing Flows › NRX Pharmaceuticals (NRXP) › Q1 2026 › vs Q4 2025
NRX Pharmaceuticals (NRXP) Q1 2026 vs Q4 2025 (quarter over quarter)
NRX Pharmaceuticals's revenue fell $135K (-11%) from $1.2M in Q4 2025 to $1.1M in Q1 2026. The biggest changes: Therapy +$58K (+8%); Procedures +$27K (+10%).
NRX Pharmaceuticals, Q1 2026: revenue $1.1M, operating margin -444.0%, net loss $1.4M, operating cash flow −$4.3M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Therapy | $760K | $702K | $58K | +8% |
| Procedures | $308K | $281K | $27K | +10% |
| Revenue | $1.1M | $1.2M | −$135K | -11% |
| Other income, net | $3.3M | $5.0M | −$1.7M | -34% |
| Net loss | $1.4M | −$360K | $1.8M | — |
| Costs & expenses | $5.8M | $6.2M | −$377K | -6% |
| Operating costs | $5.8M | $5.8M | −$17K | -0.3% |
| Cost of revenue | $631K | $408K | $223K | +55% |
| Research & development | $1.3M | $558K | $751K | +135% |
| SG&A | $3.8M | $4.6M | −$756K | -17% |
| Other operating costs | $57K | $292K | −$235K | -80% |
| Operating cash sources | $4.5M | $3.8M | $673K | +18% |
| Depreciation & amortization | $63K | $42K | $21K | +50% |
| Share-based compensation | $151K | $81K | $70K | +86% |
| Cash used in operations | $4.3M | $3.7M | $582K | +16% |
| Net loss absorbed | $1.4M | −$360K | $1.8M | — |
| Working capital & other | $3.1M | $4.2M | −$1.1M | -27% |
Questions
How much did NRX Pharmaceuticals's revenue grow quarter over quarter in Q1 2026?
NRX Pharmaceuticals's revenue fell $135K (-11%) from $1.2M in Q4 2025 to $1.1M in Q1 2026.
What drove NRX Pharmaceuticals's revenue change in Q1 2026?
Therapy +$58K (+8%); Procedures +$27K (+10%).